ABIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, ARCA biopharma's Trailing 12-Month Free Cash Flow is $-6.89 Mil, and Market Cap is $369.93 Mil. Therefore, ARCA biopharma's FCF Yield % for today is -1.86%.
The historical rank and industry rank for ARCA biopharma's FCF Yield % or its related term are showing as below:
ARCA biopharma's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.
The historical data trend for ARCA biopharma's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
-52.72 | -20.22 | -60.69 | -31.95 | -20.35 |
ARCA biopharma Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-9.49 | -23.05 | -17.14 | -23.96 | -18.96 |
For the Biotechnology subindustry, ARCA biopharma's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ARCA biopharma's FCF Yield % distribution charts can be found below:
* The bar in red indicates where ARCA biopharma's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
ARCA biopharma's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -5.014 | / | 24.6432 | |
= | -20.35% |
ARCA biopharma's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -2.634 | * | 4 | / | 55.56564 | |
= | -18.96% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARCA biopharma FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of ARCA biopharma's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
James P Flynn | director | 41 HARRIS CT, DANVILLE CA 94526 |
Funicular Funds, Lp | 10 percent owner, other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Funicular Fund, Lp | other: See Footnote 1 | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Jacob Ma-weaver | other: See Remarks | 2261 MARKET STREET, #4307, SAN FRANCISCO CA 94114 |
Christopher David Ozeroff | officer: S.V.P., General Counsel | 8001 ARISTA PLACE, SUITE 200, BROOMFIELD CO 80021 |
Robert E Conway | director | C/O ARCA BIOPHARMA, INC, 8001 ARISTA PLACE, STE 430, BROOMFIELD CO 80021 |
C. Jeffrey Dekker | officer: Chief Financial Officer | 10170 CHURCH RANCH WAY, WESTMINSTER CO 80021 |
Thomas A Keuer | officer: Chief Operating Officer | C/O ARCA BIOPHARMA, INC., 10170 CHURCH RANCH WAY, STE 100, WESTMINSTER CO 80021 |
Brian L. Selby | officer: VP, Finance | 11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER CO 80020 |
Venrock Healthcare Capital Partners Lp | 10 percent owner | 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036 |
Scott D Sandell | 10 percent owner | |
David M Mott | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Joshua Makower | 10 percent owner | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Forest Baskett | 10 percent owner | |
Peter J Barris | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
From GuruFocus
By Business Wire • 04-05-2024
By Marketwired • 08-27-2024
By PurpleRose PurpleRose • 07-15-2022
By Value_Insider Value_Insider • 10-28-2022
By PRNewswire • 04-04-2024
By sperokesalga sperokesalga • 02-24-2023
By PurpleRose PurpleRose • 08-02-2022
By Value_Insider Value_Insider • 12-19-2022
By Marketwired • 07-21-2023
By PRNewswire • 04-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.